Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background And Purpose: Platelet function during inflammation is dependent on activation by endogenous nucleotides. Non-canonical signalling via the P2Y receptor is important for these non-thrombotic functions of platelets. However, apart from ADP, the role of other endogenous nucleotides acting as agonists at P2Y receptors is unknown. This study compared the effects of ADP, Ap3A, NAD , ADP-ribose, and Up4A on platelet functions contributing to inflammation or haemostasis.

Experimental Approach: Platelets obtained from healthy human volunteers were incubated with ADP, Ap3A, NAD , ADP-ribose, or Up4A, with aggregation and fibrinogen binding measured (examples of function during haemostasis) or before exposure to fMLP to measure platelet chemotaxis (an inflammatory function). In silico molecular docking of these nucleotides to the binding pocket of P2Y receptors was then assessed.

Key Results: Platelet aggregation and binding to fibrinogen induced by ADP was not mimicked by NAD , ADP-ribose, and Up4A. However, these endogenous nucleotides induced P2Y -dependent platelet chemotaxis, an effect that required RhoA and Rac-1 activity, but not canonical PLC activity. Analysis of molecular docking of the P2Y receptor revealed distinct differences of amino acid interactions and depth of fit within the binding pocket for Ap3A, NAD , ADP-ribose, or Up4A compared with ADP.

Conclusion And Implications: Platelet function (aggregation vs motility) can be differentially modulated by biased-agonist activation of P2Y receptors. This may be due to the character of the ligand-binding pocket interaction. This has implications for future therapeutic strategies aimed to suppress platelet activation during inflammation without affecting haemostasis as is the requirement of current ant-platelet drugs.

Linked Articles: This article is part of a themed issue on Platelet purinergic receptor and non-thrombotic disease. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v181.4/issuetoc.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10952403PMC
http://dx.doi.org/10.1111/bph.16039DOI Listing

Publication Analysis

Top Keywords

p2y receptors
16
endogenous nucleotides
16
nad adp-ribose
16
adp-ribose up4a
16
ap3a nad
12
platelet
8
platelet function
8
p2y receptor
8
receptor non-thrombotic
8
adp ap3a
8

Similar Publications

Hypoxia is a key histopathological feature of glioblastoma, associated with tumor aggressiveness and therapy resistance. Glioma-associated microglia and macrophages (GAMs) are key players in the tumor microenvironment of glioblastoma and acquire immunosuppressive properties during tumor progression. We show that hypoxia alters key GAM identity genes, as it upregulates the expression of monocytic marker lectin galactoside-binding doluble 3 (Lgals3) and downregulates the homeostatic microglial markers purinergic receptor P2Y G-protein coupled 12 (P2ry12) and transmembrane protein 119 (Tmem119) in GAMs co-cultured with glioma cells and in glioblastoma patients' samples.

View Article and Find Full Text PDF

Microglia, resident immune sentinels in the brain, are crucial in responding to tissue damage, infection, damage signals like purines (ATP/ ADP), and clearing cellular debris. It is currently unknown how microglial reactivity progresses and contributes to seizure development following Theiler's Murine Encephalomyelitis Virus (TMEV) infection. Previously, our group has demonstrated that purinergic signaling in microglia is disrupted in the hippocampus of TMEV-infected mice.

View Article and Find Full Text PDF

Purpose: The P2Y receptor (P2YR) is closely associated with several inflammatory diseases in humans. Although several P2YR antagonists have been reported to date, few have been successfully developed as therapeutic drugs, and none have entered clinical trials. We aimed to obtain P2YR antagonists with high antagonistic activity and druggability for further investigation into anti-inflammatory drugs.

View Article and Find Full Text PDF

Computational discovery and repurposing of chloramphenicol succinate as a potent P2Y receptor antagonist for inflammatory bowel disease therapy.

J Adv Res

August 2025

College of Pharmaceutical Sciences, Jiangsu Key Laboratory of Neuropsychiatric Diseases and Jiangsu Province Engineering Research Center of Precision Diagnostics and Therapeutics Development, Soochow University, Suzhou 215123, China. Electronic address:

Introduction: The P2Y receptor (P2YR), a Gi-coupled receptor activated by UDP-glucose, plays a critical role in inflammatory responses and immune regulation. Existing P2YR antagonists face limitations such as poor bioavailability and structural homogeneity, hindering therapeutic development for inflammatory bowel disease (IBD). Drug repurposing offers a promising strategy to bypass traditional drug discovery challenges by leveraging approved drugs with established safety profiles.

View Article and Find Full Text PDF

Enteric glia and purinergic signaling in health and disease.

Neuropharmacology

November 2025

International Translational Neuroscience Research Institute, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China. Electronic address:

We celebrate the life of our colleague Francesco Di Virgilio, who in his very last public lecture discussed purinergic signaling in neuroglia in physiology and pathophysiology. Here, we write on a subset of a unique type of peripheral neuroglia, enteric glia that accompany enteric neurons in the enteric nervous system of the gut and act to maintain homeostasis in enteric neurocircuits. Bi-directional communication between enteric neurons and glia is majorly mediated by purines.

View Article and Find Full Text PDF